SAGE250117P15000
- 7.46
- +3.36+81.95%
Sage Therapeutics Newsroom
Truist Financial Maintains Sage Therapeutics(SAGE.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and SAGE Therapeutics (SAGE)
Mizuho Securities Maintains Sage Therapeutics(SAGE.US) With Hold Rating
Morgan Stanley Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $9
Hold Rating for SAGE Therapeutics Amid Biogen Acquisition Offer and Pipeline Challenges
RBC Raises Price Target on SAGE Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk
Sage Therapeutics Is Maintained at Overweight by Piper Sandler
Piper Sandler Initiates Sage Therapeutics(SAGE.US) With Buy Rating, Announces Target Price $9
Sage Therapeutics Price Target Cut to $6.00/Share From $10.00 by Stifel
Sage Therapeutics Analyst Ratings
Stifel Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Cuts Target Price to $6
Mizuho Securities Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Announces Target Price $10
Mizuho Securities Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Agenus (AGEN) and SAGE Therapeutics (SAGE)
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $8 to $14
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $4 to $14
Truist Financial Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
RBC Upgrades SAGE Therapeutics to Sector Perform From Underperform, Keeps Speculative Risk, $4 Price Target
SAGE Therapeutics: Analyst Reiterates Sell Rating Amid Pipeline Setbacks and Prescriber Challenges
SAGE Therapeutics: Hold Rating Amid Dalzanemdor's Phase 2 Failure and Valuation Adjustments